L’héliodermie autour du mélanome primitif comme marqueur clinique prédictif de réponse aux anti-PD-1

Russo, David; Poizeau, Florence; Dinulescu, M.; Baggio, R.; Orion, C.; Soethoudt, C.; Saillard, Colette; Man, S. Law Ping; Lesimple, Thierry; Pracht, Marc; Dupuy, Alain; Boussemart, Lise

doi:10.1016/j.annder.2020.09.068

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sunburn episodes in early childhood appeared to be more strongly related to SSM than to other variants [ 39 ]. The results of a recent study showed that helioderma could be a predictive clinical biomarker of a favorable PD-1i response [ 40 ]. Our study confirmed that SSM melanoma is a risk factor for irAEs at 7 months ( OR = 3.42; p = 0.023), 1 year ( OR = 4.40; p = 0.016) and 2 years ( OR = 5.33; p = 0.156).…”

Section: Discussionmentioning

confidence: 99%

Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases

L’Orphelin

Varey

Khammari

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: For several decades, PD‐1 has been a target in malignant melanoma (MM). PD‐1 inhibitors (nivolumab, pembrolizumab) and anti‐CTLA‐4 (CD152) (ipilimumab) have revolutionized cancer therapy. PD‐1 and CTLA‐4 inhibition leads to prolonged lymphocyte effects, which explains the cytotoxicity underlying immune‐reaction‐based adverse events (irAEs). Most irAEs occurin the first cycle of treatment at a median of 40 days. IrAEs of any grade have been observed in 68.2% of patients, with 10% of patients experiencing severe grade III/IV irAEs. Data on late‐onset irAEs are lacking. Methods: Data on patients with advanced melanoma (N = 1862) from March 2016 to March 2021 were obtained from the RicMel database, a French national multicentric biobank dedicated to the follow‐up of MM patients. Patients who received anti‐PD‐1 therapy or a combination therapy and experienced grade III‐IV irAEs were selected and analyzed at 7 months, one year and two years after treatment was initiated. Results: Superficial spreading melanoma (SSM) and previous oncological drug administration before immunotherapy are significant risk factors for lateonset irAEs over 2 years after beginning immunotherapy in the univariate and multivariate analysis. The other parameters—sex, mutational status, association of immunotherapy (PD‐1i and CTLA‐4i) and overall response—were not significantly associated with late‐onset irAEs. In our real‐life data study, the median onset time of grade III‐IV irAES was 128 days after the initiation of immune checkpoint inhibitors (ICI) therapy. Conclusions: Our study, using real‐life data, suggests that patients with SSM and those who have received previous oncological treatments are more likely to experience late‐onset grade III‐IV irAES. Further multicentric studies with wider recruitment of patients should be performed to confirm our findings, potentially leading to changes in the recommended treatment for carefully monitored at‐risk patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases

L’Orphelin

Varey

Khammari

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

Temps forts des Journées dermatologiques de Paris 2020

Aubert¹,

Frénard²

2021

European Journal of Dermatology

View full text Add to dashboard Cite

Temps forts des Journées dermatologiques de Paris 2020 Le mycosis fungoïde de l'enfant : nouvelles données françaises [1]Le mycosis fungoïde (MF) de l'enfant est une pathologie rare ; il s'agit néanmoins du premier lymphome cutané de l'enfant ; son pronostic est mal connu. La forme la plus fréquente en est le phénotype hypopigmenté CD8 + . Les auteurs présentent ici les résultats d'une étude multicentrique rétrospective de cas de MF chez des enfants et adolescents âgés de moins de 18 ans, pour lesquels le diagnostic de MF a été validé par le Groupe français d'étude des lymphomes cutanés (GFLEC) [1]. Cette étude a inclus 47 enfants, parmi lesquels 40 ont été suivis ; 72 % étaient des garçons. Quarante d'entre eux présentaient un MF de stade Ia ou Ib ; sept avaient un stade > II. Onze des 23 MF de phénotypes hypopigmenté avaient un phototype > 3, et sept des neuf MF CD8 + étaient hypopigmentés. Soixantedix pour cent (70 %) présentaient une réponse clinique après la première ligne de traitement, dont 25 % avaient une réponse clinique complète. Une transformation était rapportée chez 10 % des patients, et la persistance de la maladie à l'âge adulte était fréquente, confirmant l'évolution indolente mais prolongée du MF de l'enfant.

show abstract

L’héliodermie autour du mélanome primitif comme marqueur clinique prédictif de réponse aux anti-PD-1

Cited by 2 publications

References 0 publications

Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases

Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases

Temps forts des Journées dermatologiques de Paris 2020

Contact Info

Product

Resources

About